跳至主要内容
临床试验/NCT01130428
NCT01130428已完成1 期

Pilot Study on the Effect of Mechanical Stimulation of Bone on ATP Release in Humans in Vivo

Maastricht University Medical Center1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2010年10月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
10
试验地点
1
主要终点
Change in systemic ATP levels in response to mechanical stimulation

研究概览

简要总结

Rationale: Mechanical loading is well-known to have a strong anabolic effect on bone. It has therefore been proposed that a mechanical intervention could be an effective non-pharmacological approach to treat bone loss associated with conditions such as osteopenia and osteoporosis. Data from in vitro experiments indicate that the purine nucleotide adenosine 5'-triphosphate (ATP) is released by bone cells and mediates cellular crosstalk via P2 purinergic receptors in response to mechanical stimulation. ATP release by bone cells may thus be part of a general mechanism by which mechanical loading ultimately results in increased bone formation, but this remains to be investigated in humans in vivo. The investigators hypothesize that a mechanical intervention in humans leads to a rise in systemic ATP concentrations due to ATP release from bone.

Objective: To investigate in vivo whether a measurable increase in systemic ATP levels occurs in response to mechanical stimulation of bone in humans.

Study design: Intervention study with a non-randomized, non-blinded design. All subjects will participate in a single experiment, lasting approximately 3 hours, during which the subjects will receive a mechanical intervention at a fixed dose.

Study population: Maximally 10 healthy human volunteers (18-35 y). Intervention: Subjects will receive a gentle and safe mechanical intervention, which will be administered by means of a Juvent 1000 Vibration Platform delivering low-magnitude mechanical stimuli (i.e. vibrations) to the forearm. The mechanical stimulation will be administered at a frequency of 90 Hz and amplitude of 10 µm in an intermittent fashion, i.e. three 10-minute periods of stimulation with 10-minute rest periods in between.

Main outcome parameters: As the primary outcome parameter, a change in extracellular ATP concentrations as a result of the mechanical intervention will be assessed systemically.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Healthy human volunteers;
  • •Age 18-35 years;
  • •Cannulation of veins in forearm possible;
  • •Written informed consent.

排除标准

  • •Metabolic bone disease (osteoporosis, Paget's Disease, hyperparathyroidism, osteomalacia) or any other condition affecting bone metabolism (e.g. corticoid-treated rheumatoid arthritis);
  • •Recent bone fracture of any kind ≤ 12 months preceding the study;
  • •Blood donors.

研究组 & 干预措施

Intervention group

Experimental

As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.

干预措施: Juvent 1000 Vibration Platform (Device)

结局指标

主要结局

Change in systemic ATP levels in response to mechanical stimulation

时间窗: Pre-post treatment comparison

As the primary outcome parameter, ATP release from bone after a mechanical intervention will be investigated in humans in vivo by assessing a change in systemic concentrations of ATP and its metabolites in response to mechanical stimulation as an objective outcome measure. A change in levels of ATP (or its metabolites) is defined as the average of three concentrations after the intervention minus the average of three concentrations before the intervention (i.e. baseline).

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

撤回
不适用
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantNoncontiguous Stage II Grade 3 Follicular LymphomaChronic Eosinophilic LeukemiaAdult Acute Myeloid Leukemia in RemissionExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableNodal Marginal Zone B-cell LymphomaNoncontiguous Stage II Adult Burkitt LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Mixed Cell LymphomaNoncontiguous Stage II Adult Immunoblastic Large Cell LymphomaAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Neutrophilic LeukemiaNoncontiguous Stage II Adult Diffuse Small Cleaved Cell LymphomaNoncontiguous Stage II Grade 1 Follicular LymphomaNoncontiguous Stage II Mantle Cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Adult Hodgkin LymphomaRecurrent Malignant Testicular Germ Cell TumorRecurrent Marginal Zone LymphomaAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Chronic Phase Chronic Myelogenous LeukemiaDisseminated NeuroblastomaNoncontiguous Stage II Grade 2 Follicular LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent NeuroblastomaStage III Adult Diffuse Mixed Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell LymphomaStage IV Ovarian Epithelial CancerStage IV Small Lymphocytic LymphomaBlastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesRecurrent Adult Lymphoblastic LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaStage II Ovarian Germ Cell TumorStage III Chronic Lymphocytic LeukemiaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage IV Adult Burkitt LymphomaStage IV Marginal Zone LymphomaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesNoncontiguous Stage II Adult Lymphoblastic LymphomaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Ovarian Epithelial CancerChronic Myelomonocytic LeukemiaNoncontiguous Stage II Marginal Zone LymphomaNoncontiguous Stage II Small Lymphocytic LymphomaPlasma Cell NeoplasmPoor Prognosis Metastatic Gestational Trophoblastic TumorRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRefractory Chronic Lymphocytic LeukemiaSecondary Acute Myeloid LeukemiaSplenic Marginal Zone LymphomaStage II Ovarian Epithelial CancerStage III Adult Diffuse Small Cleaved Cell LymphomaStage III Adult Immunoblastic Large Cell LymphomaStage III Grade 3 Follicular LymphomaStage III Malignant Testicular Germ Cell TumorStage IIIA Breast CancerStage IIIC Breast CancerStage IV Adult Diffuse Large Cell LymphomaStage IV Adult Hodgkin LymphomaStage IV Adult Lymphoblastic LymphomaProlymphocytic LeukemiaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Ovarian Germ Cell TumorSecondary Myelodysplastic SyndromesStage III Adult Burkitt LymphomaStage III Adult Hodgkin LymphomaStage III Marginal Zone LymphomaStage IIIB Breast CancerStage IV Adult Diffuse Small Cleaved Cell LymphomaStage IV Adult Immunoblastic Large Cell LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaRefractory Hairy Cell LeukemiaRelapsing Chronic Myelogenous LeukemiaStage III Adult Diffuse Large Cell LymphomaStage III Adult Lymphoblastic LymphomaStage III Ovarian Epithelial CancerStage III Ovarian Germ Cell TumorStage III Small Lymphocytic LymphomaStage IV Adult Diffuse Mixed Cell LymphomaStage IV Breast CancerStage IV Grade 3 Follicular LymphomaStage IV Ovarian Germ Cell TumorPrimary Myelofibrosis
NCT01558778Roswell Park Cancer Institute
已完成
不适用
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRDRenal Osteodystrophy
NCT00364234National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)30
已完成
不适用
Pilot study on the effect of mechanical stimulation of bone on ATP release in humans in vivobone fragility10005959osteoporosis
NL-OMON34857niversiteit Maastricht10
已完成
不适用
Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia NervosaAnorexia Nervosa
NCT01100567Boston Children's Hospital101
已完成
不适用
Osteoanabolic response to mechanical stimulation in patients with monoclonal gammopathy of undetermined significanceD47.2Monoclonal gammopathy of undetermined significance (MGUS)
DRKS00014792Medizinische Klinik und Poliklinik II Universitätsklinikum Würzburg15